natgillin/translations-raw huggingface dataset:
If you suffer from renal impairment (kidney problems), your doctor should closely monitor your kidney function and if necessary adapt the memantine doses accordingly. 
Ako imate oštećenje bubrežne funkcije (probleme s bubrezima), liječnik treba pažljivo pratiti funkciju Vaših bubrega i ovisno o njoj prilagoditi dozu memantina, ako je to potrebno.
Memantine Accordbelongs to a group of medicines known as anti-dementia medicines. 
Memantin Accord se ubraja u skupinu lijekova poznatih kao lijekovi protiv demencije.
At a dose of memantine of 20 mg per day the CSF levels match the ki-value (ki = inhibition constant) of memantine, which is 0.5 μmol in human frontal cortex. 
Pri dozi od 20 mg memantina dnevno razine u CSL-u odgovaraju ki-vrijednosti (ki = konstanta inhibicije) memantina koja u frontalnom korteksu kod ljudi iznosi 0,5 µmol.
Week 3 (day 15-21): 
3. tjedan (15. - 21. dan):
If you take a large overdose of Memantine Accord, contact your doctor or get medical advice, as you may need medical attention. 
Ako ste uzeli preveliku dozu lijeka Memantin Accord, javite se Vašem liječniku za savjet, jer bi Vam mogla zatrebati medicinska pomoć.
The study showed beneficial effects of memantine treatment in comparison to placebo at 6 months (observed cases analysis for the clinician´s interview based impression of change (CIBIC-plus): p = 0.025; Alzheimer´s disease cooperative study - activities of daily living (ADCS-ADLsev): p = 0.003; severe impairment battery (SIB): p = 0.002). 
U 6. mjesecu ispitivanja pokazani su povoljni učinci liječenja memantinom u usporedbi s placebom (analiza opaženih slučajeva za promjene bazirane na dojmu kliničara nakon intervjua (CIBIC-plus): p=0,025; kooperativno ispitivanje Alzheimerove bolesti - aktivnosti svakodnevnog života (ADCS-ADLsev): p=0,003; skup znakova teške onesposobljenosti (SIB): p=0,002).
Medicinal products subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2). 
Lijek se izdaje na ograničeni recept (vidjeti Dodatak I: Sažetak opisa svojstava lijeka, dio 4.2).
Memantine-treated patients showed a statistically significantly better effect than placebo-treated patients on the primary endpoints: Alzheimer´s disease assessment scale (ADAS-cog) (p = 0.003) and CIBIC-plus (p = 0.004) at week 24 last observation carried forward (LOCF). 
Bolesnici liječeni memantinom pokazali su statistički značajno bolji učinak nego bolesnici koji su primali placebo u pogledu primarnih ishoda: skala procjene Alzheimerove bolesti (ADAS-cog) (p=0,003) i CIBIC-plus (p=0,004) u 24. tjednu liječenja (zadnje opažanje preneseno dalje (LOCF)).
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu. 
Detaljne informacije o ovom lijeku dostupne su na web stranici Europske Agencije za lijekove http://www.ema.europa.eu.
Do not use Memantine Accord after the expiry date which is stated on the carton and the blister after EXP. 
Memantin Accord se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kartonskoj kutiji i blisteru nakon “Rok valjanosti”.
Pack sizes of 14, 28, 30, 42, 50, 56, 98, 100 and 112 tablets are presented. 
Postoje veličine pakiranja od 14, 28, 30, 42, 50, 56, 98, 100 i 112 tableta.
Memantine Accord acts on these NMDA-receptors improving the transmission of nerve signals and the memory. 
Memantin Accord djeluje na navedene NMDA receptore poboljšavajući prijenos živčanih signala i pamćenje.
Uncommon Confusion Uncommon Hallucinations1 Not known Psychotic reactions2 
Manje često konfuzija Manje često halucinacije1 Nepoznato psihotične reakcije2
MARKETING AUTHORISATION HOLDER Accord Healthcare S.L.U. 
NOSITELJ ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Accord Healthcare S.L.U.
INNER CARTON FOR BLISTER PACK 
UNUTARNJA KUTIJA ZA BLISTER
What Memantine Accord contains 
Što Memantin Accord sadrži
Memantine Accordis used for the treatment of patients with moderate to severe Alzheimer's disease. 
Memantin Accord se koristi za liječenje bolesnika s umjerenom do teškom Alzheimerovom bolešću.
Memantine Accord belongs to a group of medicines called NMDA-receptor antagonists. 
Memantin Accord spada u skupinu lijekova poznatih kao antagonisti NMDA receptora.
In these situations the treatment should be carefully supervised, and the clinical benefit of Memantine Accord assessed by your doctor on a regular basis. 
U tim slučajevima liječenje mora biti pažljivo nadzirano, a Vaš liječnik treba redovito procjenjivati kliničku korist od uzimanja lijeka Memantin Accord.
• Headache, sleepiness, constipation, elevated liver function test, dizziness, balance disorders, shortness of breath, high blood pressure and drug hypersensitivity 
• glavobolja, pospanost, zatvor, povišene razine testa jetrene funkcije, omaglica, poremećaji ravnoteže, nedostatak zraka, visoki krvni tlak i preosjetljivost na lijek.
amantadine, ketamine, dextromethorphan dantrolene, baclofen cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine hydrochlorothiazide (or any combination with hydrochlorothiazide) anticholinergics (substances generally used to treat movement disorders or intestinal cramps) anticonvulsants (substances used to prevent and relieve seizures) barbiturates (substances generally used to induce sleep) dopaminergic agonists (substances such as L-dopa, bromocriptine) neuroleptics (substances used in the treatment of mental disorders) oral anticoagulants 
amantadina, ketamina, dekstrometorfana dantrolena, baklofena cimetidina, ranitidina, prokainamida, kinidina, kinina, nikotina hidroklorotiazida (ili bilo koja kombinacija s hidroklorotiazidom) antikolinergika (lijekovi koje se uglavnom koriste za liječenje poremećaja kretanja ili crijevnih grčeva) antikonvulziva (lijekovi koji se koriste za sprječavanje i ublažavanje napadaja) barbiturata (lijekovi koji se uglavnom koriste za uspavljivanje) dopaminergičkih agonista (lijekovi kao što su L-dopa, bromokriptin) neuroleptika (lijekovi koji se koriste za liječenje mentalnih poremećaja) oralnih antikoagulansa.
• Tiredness, fungal infections, confusion, hallucinations, vomiting, abnormal gait, heart failure and venous blood clotting (thrombosis/thromboembolism). 
• umor, gljivične infekcije, smetenost, halucinacije, povraćanje, poremećaj hoda, zatajenje srca i zgrušavanje venske krvi (tromboza/tromboembolija).
memantine hydrochloride 
memantinklorid
If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 
U slučaju daljnjih pitanja u vezi s primjenom ovog lijeka obratite se svom liječniku ili ljekarniku.
Women taking Memantine Accord should not breast-feed. 
Žene koje uzimaju Memantin Accord ne smiju dojiti.
one and a half 10 mg tablet week 4 and beyond two 10 mg tablets once a day 
3. tjedan jedna i pol tableta od 10 mg 4. tjedan i nadalje dvije tablete od 10 mg jednom dnevno
EU/1/13/880/013 28 film-coated tablets 
EU/1/13/880/013 28 filmom obloženih tableta
Daily doses of 20 mg lead to steady-state plasma concentrations of memantine ranging from 70-150 ng/ml (0.5-1μmol) with large interindividual variations. 
Dnevne doze od 20 mg dovode do plazmatskih koncentracija memantina u stanju dinamičke ravnoteže u rasponu od 70 do 150 ng/ml (0,5 - 1 µmol) s velikim interindividualnim razlikama.
How to store Memantine Accord 6. 
Kako čuvati Memantin Accord 6.
Memantine Accord film-coated tablets are available in blister packs (PVC/PE/PVDC-aluminium blister) of 14 tablets, 28 tablets, 42 tablets, 56 tablets and 98 tablets. 
Memantin Accord filmom obložene tablete su dostupne u pakiranjima s blisterima (PVC/PE/PVDCaluminijski blister) od 14 tableta, 28 tableta, 42 tablete, 56 tableta i 98 tableta.
Lactose monohydrate Microcrystalline cellulose Silica, colloidal anhydrous Crospovidone Magnesium stearate 
Jezgra tablete laktoza hidrat celuloza, mikrokristalična silicijev dioksid, koloidni, bezvodni krospovidon magnezijev stearat
CARTON FOR 28 TABLETS - TREATMENT INITIATION PACK4 WEEK TREATMENT SCHEDULE 
KUTIJA ZA 28 TABLETA - PAKIRANJE ZA POČETAK
Main human metabolites are N-3,5-dimethyl-gludantan, the isomeric mixture of 4-and 6-hydroxymemantine, and 1-nitroso-3,5-dimethyl-adamantane. 
Glavni metaboliti kod ljudi su N-3,5-dimetil-gludantan, izomerna mješavina 4- i 6-hidroksi-memantina i 1-nitrozo-3,5dimetil-adamantan.
- The active substance is memantine hydrochloride. 
Djelatna tvar je memantinklorid.
In volunteers with normal kidney function, total clearance (Cltot) amounts to 170 ml/min/1.73 m² and part of total renal clearance is achieved by tubular secretion. 
Kod dobrovoljaca s normalnom funkcijom bubrega ukupni klirens (Cltot) iznosi do 170 ml/min/1,73 m², a dio ukupnog bubrežnog klirensa postiže se tubularnom sekrecijom.
In clinical trials in mild to severe dementia, involving 1,784 patients treated with memantine and 1,595 patients treated with placebo, the overall incidence rate of adverse reactions with memantine did not differ from those with placebo; the adverse reactions were usually mild to moderate in severity. 
U kliničkim ispitivanjima blage do teške demencije u kojima je 1784 bolesnika liječeno memantinom, a 1595 ih je dobivalo placebo, sveukupna stopa incidencije nuspojava u skupini liječenoj memantinom nije se razlikovala od stope incidencije nuspojava u skupini koja je primala placebo.
The patient should take two 10 mg film-coated tablets (20 mg) per day. 
Bolesnik treba uzimati dvije filmom obložene tablete od 10 mg (20 mg) dnevno.
Week 4 (day 22-28): 
4. tjedan (22. - 28. dan):
Memantine Accord film-coated tablets are available in blister packs (PVC/PE/PVDC-aluminium blister) of 14 tablets, 28 tablets, 30 tablets, 42 tablets, 50 tablets, 56 tablets, 98 tablets, 100 tablets and 112 tablets. 
Memantin Accord filmom obložene tablete dostupne su u pakiranjima s blisterima (PVC/PE/PVDCaluminijski blister) 14 tableta, 28 tableta, 30 tableta, 42 tablete, 50 tableta, 56 tableta, 98 tableta, 100 tableta i 112 tableta.
In a study using orally administered 14C-memantine, a mean of 84 % of the dose was recovered within 
U ispitivanju u kojem je korišten oralno primijenjen 14C-memantin uklonjeno je prosječno 84% doze unutar 20 dana, a više od 99% izlučeno je putem bubrega.
Uncommon Vomiting Not known Pancreatitis2 
Nepoznato pankreatitis2
The following adverse reactions listed in the table below have been accumulated in clinical studies with memantine and since its introduction in the market. 
U sljedećoj tablici prikazane su nuspojave prikupljene tijekom kliničkih ispitivanja s memantinom i nakon stavljanja lijeka u promet.
It allows continued monitoring of the benefit/risk balance of the medicinal product. 
Bitno je prijaviti moguće nuspojave nakon što je lijek stavljen u promet jer to omogućava kontinuirano kontroliranje ravnoteže koristi/rizika datog lijeka.
Blister packs containing 28 tablets with 7 tablets of 5 mg, 7 tablets of 10 mg, 7 tablets of 15 mg and 7 tablets of 20 mg. 
Blister pakiranje sadržava 28 tableta od čega 7 tableta od 5 mg, 7 tableta od 10 mg, 7 tableta od 15 mg i 7 tableta od 20 mg
Memantine Accord contains lactose. 
Memantin Accord sadržava laktozu.
Uncommon (may affect up to 1 in 100 people): 
Manje česte (mogu se javiti kod do 1 na 100 osoba):
Memantine Accord contains lactose 
Memantin Accord sadržava laktozu
Uncommon Fungal infections 
Manje često gljivične infekcije
Memantine Accord 5 mg, 10 mg, 15 mg; 20 mg film-coated tablets 
Memantin Accord 5 mg, 10 mg, 15 mg, 20 mg filmom obložene tablete
In patients with mildly impaired renal function (creatinine clearance 50-80 ml/min) no dose adjustment is required. 
Kod bolesnika s blagim oštećenjem funkcije bubrežne funkcije (klirens kreatinina 50-80 ml/min) nije potrebna prilagodba doze.
Take one 5 mg tablet once a day (white) for 7 days. 
Uzimajte jednu tabletu od 5 mg jednom dnevno (bijelu) tijekom 7 dana.
A pivotal monotherapy study of memantine in the treatment of mild to moderate Alzheimer's disease (MMSE total scores at baseline of 10-22) included 403 patients. 
U pivotalno ispitivanje monoterapije memantinom u liječenju blage do umjerene Alzheimerove bolesti (početne vrijednosti ukupnog MMSE od 10 do 22) bila su uključena 403 bolesnika.
Hypertension Uncommon Venous thrombosis/thromboembolism 
Često hipertenzija Manje često venska tromboza/tromboembolija
15 mg tablet week 4 and beyond 20 mg tablets once a day Maintenance dose 
3. tjedan tableta od 15 mg 4. tjedan i nadalje tableta od 20 mg jednom dnevno
Administration of Memantine Accord is not recommended in patients with severe hepatic impairment. 
Ne preporučuje se primjena lijeka Memantin Accord kod bolesnika s teškim oštećenjem jetrene funkcije.
In patients with severe renal impairment (creatinine clearance 5-29 ml/min) daily dose should be 10 mg per day. 
Kod bolesnika s teškim oštećenjem bubrežne funkcije (klirens kreatinina 5-29 ml/min) dnevna doza bi trebala biti 10 mg dnevno.
One treatment initiation pack contains 28 tablets in 4 blisters with 7 tablets of Memantine Accord 5 mg, 7 tablets of Memantine Accord 10 mg, 7 tablets of Memantine Accord 15 mg and 7 tablets of Memantine Accord 20 mg. 
Jedno pakiranje za početak liječenja sadržava 28 tableta u 4 blistera sa 7 Memantin Accord tableta od 5 mg, 7 Memantin Accord tableta od 10 mg, 7 Memantin Accord tableta od 15 mg i 7 Memantin Accord tableta od 20 mg.
On the basis of the clinical studies, the recommended dose for patients over the age of 65 years is 20 mg per day as described above. 
Temeljem kliničkih ispitivanja preporučena doza za bolesnike starije od 65 godina iznosi 20 mg na dan, kao što je gore opisano.
Memantine Accord contains the active substance memantine hydrochloride. 
Memantin Accord sadrži djelatnu tvar memantinklorid.
14 x 1 film-coated tablets 28 x 1 film-coated tablets 56 x 1 film-coated tablets 98 x 1 film-coated tablets 
14 x 1 filmom obložena tableta 28 x 1 filmom obložena tableta 56 x 1 filmom obložena tableta 98 x 1 filmom obložena tableta
On the basis of the clinical studies, the recommended dose for patients over the age of 65 years is 20 mg per day (20 mg tablets once a day) as described above. 
Temeljem kliničkih ispitivanja preporučena doza za bolesnike starije od 65 godina iznosi 20 mg na dan (tablete od 20 mg jednom dnevno), kao što je gore opisano.
Pack sizes of 14, 28, 42, 56 and 98 tablets are presented. 
Tablete se nalaze u pakiranjima od 14, 28, 42, 56 i 98 tableta.
In postmarketing experience these events have been reported in patients treated with memantine. 
Ovi su događaji prijavljeni u postmarketinškom razdoblju kod bolesnika liječenih memantinom.
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine. 
Nuspojave možete prijaviti i izravno putem nacionalnog sustava prijavljivanja navedenog uDodatku V.
7 x Memantine Accord 10 mg 
7 x Memantin Accord 10 mg
7 x Memantine Accord 20 mg 
7 x Memantin Accord 20 mg
Take one 20 mg tablet per day (pale red to greyred, scored) for 7 days. 
Uzimajte jednu tabletu od 20 mg dnevno (blijedocrvenu do sivo-crvenu, s razdjelnom crtom) tijekom 7 dana.
7 x Memantine Accord 15 mg 
7 x Memantin Accord15 mg
When patients were identified with concurrent worsening in all three domains, results showed a statistically significant effect of memantine in preventing worsening, as twice as many placebo-treated 7 patients as memantine-treated patients showed worsening in all three domains (21 % vs. 11 %, p < 0.0001). 
U skupini bolesnika liječenih placebom bilo je dvostruko više pogoršanja (7) u sva tri područja nego u skupini bolesnika liječenih memantinom (21 % naspram 11 %, p<0,0001).
14 film-coated tablets 28 film-coated tablets 30 film-coated tablets 42 film-coated tablets 50 film-coated tablets 56 film-coated tablets 98 film-coated tablets 100 film-coated tablets 112 film-coated tablets 
28 filmom obloženih tableta. 30 filmom obloženih tableta 42 filmom obložene tablete 50 filmom obloženih tableta 56 filmom obloženih tableta 98 filmom obloženih tableta 100 filmom obloženih tableta 112 filmom obloženih tableta
Reporting suspected adverse reactions after authorisation of the medicinal product is important. 
Bitno je prijavljivati sumnje na nuspojave nakon dobivanja odobrenja za lijek jer se time omogućava kontinuirano praćenje omjera koristi i rizika lijeka.
How does Memantine Accord work 
Kako djeluje Memantin Accord
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 5 mg of memantine hydrochloride equivalent to 4.15 mg memantine. 
2. KVALITATIVNI I KVANTITATIVNI SASTAV Svaka filmom obložena tableta sadržava 5 mg memantinklorida, što odgovara 4,15 mg memantina.
How to take Memantine Accord 
Kako uzimati Memantin Accord
On the basis of the clinical studies, the recommended dose for patients over the age of 65 years is 20 mg per day (two 10 mg tablets once a day) as described above. 
Temeljem kliničkih ispitivanja preporučena doza za bolesnike starije od 65 godina iznosi 20 mg dnevno (dvije filmom obložene tablete od 10 mg jednom dnevno), kao što je gore opisano.
Your doctor will tell you whether your illness allows you to drive and to use machines safely.Also, Memantine Accord may change your reactivity, making driving or operating machinery inappropriate. 
Liječnik će Vam reći dopušta li Vam bolest sigurno upravljanje vozilima i rad na strojevima.
Take one 10 mg tablet once a day (white, scored) for 7 days. 
Uzimajte jednu tabletu od 10 mg jednom dnevno (bijelu, s razdjelnom crtom) tijekom 7 dana.
Elevated liver function test Not known Hepatitis 
Često povišene vrijednosti testova jetrene funkcije
Uncommon Confusion Uncommon Hallucinations1 
Nepoznato somnolencija konfuzija halucinacije1 psihotične reakcije2
Memantine Accord 10 mg tablets are also available in perforated unit dose calendar blister in pack-sizes of 14x1, 28x1, 56x1 or 98x1 tablet. 
Memantin Accord 10 mg tablete također su dostupne u perforiranim kalendarskim blisterima djeljivim na jedinične doze u veličinama pakiranja od 14x1, 28x1, 56x1 ili 98x1 tableta.
EU/1/13/880/001 EU/1/13/880/002 EU/1/13/880/003 EU/1/13/880/004 EU/1/13/880/005 EU/1/13/880/006 EU/1/13/880/007 EU/1/13/880/008 EU/1/13/880/014 EU/1/13/880/016 EU/1/13/880/017 EU/1/13/880/018 EU/1/13/880/019 
EU/1/13/880/003 EU/1/13/880/004 EU/1/13/880/005 EU/1/13/880/006 EU/1/13/880/007 EU/1/13/880/008 EU/1/13/880/014 EU/1/13/880/016 EU/1/13/880/017 EU/1/13/880/018 EU/1/13/880/019
Memantine Accord 20 mg tablets are also available in perforated unit dose calendar blister in packsizes of 14x1, 28x1, 56x1 or 98x1 tablet. 
Memantin Accord 20 mg tablete također su dostupne u perforiranim kalendarskim blisterima djeljivim na jedinične doze u veličinama pakiranja od 14x1, 28x1, 56x1 ili 98x1 tableta.
Memantine Accord film-coated tablets are also available in perforated unit dose calendar blister in pack-sizes of 14x1, 28x1, 56x1 or 98x1 tablet. 
Memantin Accord filmom obložene tablete također su dostupne u perforiranim kalendarskim blisterima djeljivim na jedinične doze u veličinama pakiranja od 14x1, 28x1, 56x1 ili 98x1 tableta.
Take one 15 mg tablet once a day (orange to grey-orange) for 7 days. 
Uzimajte jednu tabletu od 15 mg jednom dnevno (narančastu do sivo-narančastu) tijekom 7 dana.
Excipientwith known effect: each film-coated tablet contains 73.80 mg lactose (as monohydrate). 
Pomoćna tvar s poznatim učinkom: svaka filmom obložena tableta sadržava 73,80 mg laktoze (u obliku hidrata).
NAME OF THE MARKETING AUTHORISATION HOLDER Accord 
ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Accord
Excipientwith known effect: each film-coated tablet contains 295.18 mg lactose (as monohydrate). 
Pomoćna tvar s poznatim učinkom: svaka filmom obložena tableta sadržava 295,18 mg laktoze (u obliku hidrata).
Memantine Accord 20 mg film-coated tablets 
Memantin Accord 20 mg filmom obložene tablete
Film-coated tablets 14 film-coated tablets 28 film-coated tablets 42 film-coated tablets 56 film-coated tablets 98 film-coated tablets 
14 filmom obložene tablete 28 filmom obloženih tableta 42 filmom obložene tablete 56 filmom obloženih tableta 98 filmom obloženih tableta
Each film-coated tablet contains 5 mg memantine hydrochloride equivalent to 4.15 mg memantine. 
Svaka filmom obložena tableta sadrži 5 mg memantinklorida, što odgovara 4,15 mg memantina.
Hypromellose Polysorbate 80 Macrogol 400 
Ovojnica tablete hipromeloza polisorbat 80 makrogol 400 titanijev dioksid (E 171)
This includes any possible side effects not listed in this leaflet.See section 4. 
To uključuje i svaku moguću nuspojavu koja nije navedena u ovoj uputi.
Excipientwith known effect: each film coated tablet contains 183.13 mg lactose (as monohydrate). 
Pomoćna tvar s poznatim učinkom: svaka filmom obložena tableta sadržava 183,13 mg laktoze (u obliku hidrata).
Memantine Accord 10 mg film-coated tablets 
Memantin Accord 10 mg filmom obložene tablete
Each film-coated tablet contains 5/10/15/20 mg of memantine hydrochloride equivalent to 4.15/8.31/12.46/16.62 mg memantine - The other ingredients are lactose monohydrate, microcrystalline cellulose, colloidal anhydrous silica, crospovidone, magnesium stearate, all in the tablet core; hypromellose, polysorbate 80, macrogol 400, titanium dioxide (E 171), and additional for Memantine Accord 15 mg and Memantine Accord 20 mg film-coated tablets iron oxide yellow and red (E 172), all in the tablet coating 
Pomoćne tvari su laktoza hidrat, mikrokristalična celuloza, koloidni bezvodni silicijev dioksid, krospovidon i magnezijev stearat sve u jezgri tablete; te hipromeloza, polisorbat 80, makrogol 400, titanijev dioksid (E171) i dodatno za Memantin Accord 15 mg i Memantin Accord 20 mg filmom obložene tablete žuti i crveni željezov oksid (E172), sve u ovojnici tablete.
Memantine Accord 5 mg film-coated tablets Memantine Accord 10 mg film-coated tablets Memantine Accord 15 mg film-coated tablets Memantine Accord 20 mg film-coated tablets 
Memantin Accord 5 mg filmom obložene tablete Memantin Accord 10 mg filmom obložene tablete Memantin Accord 15 mg filmom obložene tablete Memantin Accord 20 mg filmom obložene tablete
The patient should take one 20 mg film-coated tablet per day for 7 days. 
Bolesnik treba uzimati jednu filmom obloženu tabletu od 20 mg dnevno, tijekom 7 dana.
Week 1 (day 1-7): The patient should take one 5 mg film-coated tablet per day (white) for 7 days. 
1. tjedan (1. - 7. dan): Bolesnik treba uzimati jednu filmom obloženu tabletu od 5 mg (bijelu) dnevno tijekom 7 dana.
The patient should take one 15 mg film-coated tablet per day for 7 days. 
Bolesnik treba uzimati jednu filmom obloženu tabletu od 15 mg dnevno, tijekom 7 dana.
How to take Memantine Accord 4. 
Kako uzimati Memantin Accord 4. Moguće nuspojave
Memantine Accord 5 mg film-coated tablets Memantine Accord 10 mg film-coated tablets Memantine Accord 15 mg film-coated tablets Memantine Accord 20 mg film-coated tablets memantine hydrochloride 
Memantin Accord 5 mg filmom obložene tablete Memantin Accord 10 mg filmom obložene tablete Memantin Accord 15 mg filmom obložene tablete Memantin Accord 20 mg filmom obložene tablete memantinklorid
Each film-coated tablet contains 20 mg of memantine hydrochloride equivalent to 16.62 mg memantine - The other ingredients are lactose monohydrate, microcrystalline cellulose, colloidal anhydrous silica, crospovidone, magnesium stearate, all in the tablet core; hypromellose, polysorbate 80, macrogol 400, titanium dioxide (E 171), iron oxide red (E 172), iron oxide yellow (E 172) all in the tablet coating 
Pomoćne tvari su: laktoza hidrat, mikrokristalična celuloza, , koloidni bezvodni silicijev dioksid, krospovidon i magnezijev stearat, sve u jezgri tablete; te hipromeloza, polisorbat 80, makrogol 400, titanijev dioksid (E171), crveni željezov oksid (E171), žuti željezov oksid (E172), sve u ovojnici tablete.
What is Memantine Accord used for 
Za što se Memantin Accord koristi
The 5 mg film-coated tablets are white, oblong, coated tablets, debossed with "MT" on one side and "5" on the other side. 
Filmom obložene tablete od 5 mg su bijele, duguljaste, obložene tablete, s utisnutom oznakom ‘MT' na jednoj strani i ‘5' na drugoj strani.
How to store Memantine Accord 
Kako čuvati Memantin Accord